IL22 and Other metabolic disease: Previous studies indicated that AhR activation by the classical AhR agonist of Ficz inhibited the development of experimental colitis (28), metabolic disorders (6), EAE (52), and chronic inflammation (42) via IL-22 production or direct transcriptional regulation, which are related to the restoration of barrier function (54).